We are live on
!
Find out more
ANI Pharmaceuticals
ANIP
ANIP
182 hedge funds and large institutions have $764M invested in ANI Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 55 increasing their positions, 53 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
436% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $248K
2.7% more ownership
Funds ownership: 65.09% → 67.78% (+2.7%)
4% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 53
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less capital invested
Capital invested by funds: $766M → $764M (-$2.8M)
9% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 34
2% less funds holding
Funds holding: 186 → 182 (-4)
Holders
182
Holders Change
-4
Holders Change %
-2.15%
% of All Funds
2.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
31
Increased
55
Reduced
53
Closed
34
Calls
$1.33M
Puts
$248K
Net Calls
+$1.08M
Net Calls Change
+$1.38M
Top Buyers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$15.3M |
| 2 |
Morgan Stanley
New York
|
+$13.4M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$12.7M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$11M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.62M |
